Patents by Inventor Swen Hoelder
Swen Hoelder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240417388Abstract: The present invention relates to compounds of Formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X1, X2, R1, R2 and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.Type: ApplicationFiled: August 8, 2024Publication date: December 19, 2024Inventors: Benjamin Richard Bellenie, Michael K. Carter, Kwai Ming Jack Cheung, Owen Alexander Davis, Swen Hoelder, Matthew Garth Lloyd, Ana Varela Rodriguez, Hannah Woodward, Paolo Innocenti
-
Patent number: 12110286Abstract: The present invention relates to compounds of Formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X1, X2, R1, R2 and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.Type: GrantFiled: May 25, 2018Date of Patent: October 8, 2024Assignees: Cancer Research Technology Limited, The Institute of Cancer ResearchInventors: Benjamin Richard Bellenie, Michael K. Carter, Kwai Ming Jack Cheung, Owen Alexander Davis, Swen Hoelder, Matthew Garth Lloyd, Ana Varela Rodriguez, Hannah Woodward, Paolo Innocenti
-
Publication number: 20240217987Abstract: The present invention relates to compounds that function as inhibitors of BCL6 (B-cell lymphoma 6) activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.Type: ApplicationFiled: October 14, 2020Publication date: July 4, 2024Inventors: Benjamin Richard BELLENIE, Alfie BRENNAN, Ming Jack CHEUNG, Owen Alexander DAVIS, Alice Claire HARNDEN, Swen HOELDER, Rosemary HUCKVALE
-
Patent number: 11897877Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: GrantFiled: May 13, 2021Date of Patent: February 13, 2024Assignee: Cancer Research Technology LimitedInventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Gaston Andre Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Publication number: 20230287003Abstract: The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X1, X2, R1, R2, R30, R31 and Ring A are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.Type: ApplicationFiled: October 18, 2022Publication date: September 14, 2023Inventors: Benjamin Richard Bellenie, Kwai Ming Jack Cheung, Owen Alexander Davis, Swen Hoelder, Rosemary Huckvale, Gavin Collie, Mirco Meniconi, Alfie Brennan, Matthew Garth Lloyd
-
Publication number: 20220402912Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: ApplicationFiled: May 13, 2021Publication date: December 22, 2022Inventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Gaston Andre Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Patent number: 11512095Abstract: The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X1, X2, R1, R2, R30, R31 and Ring A are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.Type: GrantFiled: April 12, 2019Date of Patent: November 29, 2022Assignees: The Institute of Cancer Research: Royal Cancer Hospital, Cancer Research Technology LimitedInventors: Benjamin Richard Bellenie, Kwai Ming Jack Cheung, Owen Alexander Davis, Swen Hoelder, Rosemary Huckvale, Gavin Collie, Mirco Meniconi, Alfie Brennan, Matthew Garth Lloyd
-
Patent number: 11161839Abstract: The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: Formula I wherein X1, X2, X3, R1, R2, R3, R4 and R5 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.Type: GrantFiled: May 25, 2018Date of Patent: November 2, 2021Assignees: The Institute of Cancer Research: Royal Cancer Hospital, Cancer Research Technology LimitedInventors: Benjamin Richard Bellenie, Kwai Ming Jack Cheung, Owen Alexander Davis, Swen Hoelder, Rosemary Huckvale, Matthew Garth Lloyd
-
Publication number: 20210206756Abstract: The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: Formula I wherein X1, X2, X3, R1, R2, R3, R4 and R5 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.Type: ApplicationFiled: May 25, 2018Publication date: July 8, 2021Inventors: Benjamin R. Bellenie, Kwai Ming Jack Cheung, Owen Alexander Davis, Swen Hoelder, Rosemary Huckvale, Matthew Garth Lloyd
-
Patent number: 11046688Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: GrantFiled: October 10, 2019Date of Patent: June 29, 2021Assignee: Cancer Research Technology LimitedInventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Gaston Andre Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Publication number: 20210163497Abstract: The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X1, X2, R1, R2, R30, R31 and Ring A are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.Type: ApplicationFiled: April 12, 2019Publication date: June 3, 2021Inventors: Benjamin Richard Bellenie, Kwai Ming Jack Cheung, Owen Alexander Davis, Swen Hoelder, Rosemary Huckvale, Gavin Collie, Mirco Meniconi, Alfie Brennan, Matthew Garth Lloyd
-
Publication number: 20210147382Abstract: The present invention relates to compounds of Formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X1, X2, R1, R2 and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.Type: ApplicationFiled: May 25, 2018Publication date: May 20, 2021Inventors: Benjamin Richard Bellenie, Michael K. Carter, Kwai Ming Jack Cheung, Owen Alexander Davis, Swen Hoelder, Matthew Garth Lloyd, Ana Varela Rodriguez, Hannah Woodward, Paolo Innocenti
-
Publication number: 20200165241Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: ApplicationFiled: October 10, 2019Publication date: May 28, 2020Inventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Gaston Andre Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Patent number: 10479788Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: GrantFiled: January 8, 2018Date of Patent: November 19, 2019Assignee: Cancer Research Technology LimitedInventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Patent number: 10399974Abstract: The present invention relates to compounds of formula I: wherein R1, R2, R3 and R4 are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: GrantFiled: January 3, 2018Date of Patent: September 3, 2019Assignee: Cancer Research Technology LimitedInventors: Hannah Woodward, Paolo Innocenti, Sebastien Naud, Julian Blagg, Swen Hoelder
-
Patent number: 10188642Abstract: The present invention relates to compounds of formula II wherein X, Y, R2, R3, R4 and Ar are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: GrantFiled: December 22, 2017Date of Patent: January 29, 2019Assignee: Cancer Research Technology LimitedInventors: Swen Hoelder, Julian Blagg, Kwai-Ming Jack Cheung, Butrus Atrash, Peter Sheldrake
-
Publication number: 20180194761Abstract: The present invention relates to compounds of formula I: wherein R1, R2, R3 and R4 are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: ApplicationFiled: January 3, 2018Publication date: July 12, 2018Inventors: Hannah Woodward, Paolo Innocenti, Sebastien Naud, Julian Blagg, Swen Hoelder
-
Publication number: 20180141944Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: ApplicationFiled: January 8, 2018Publication date: May 24, 2018Inventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Publication number: 20180117032Abstract: The present invention relates to compounds of formula II wherein X, Y, R2, R3, R4 and Ar are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: ApplicationFiled: December 22, 2017Publication date: May 3, 2018Inventors: Swen Hoelder, Julian Blagg, Kwai-Ming Jack Cheung, Butrus Atrash, Peter Sheldrake
-
Patent number: 9902721Abstract: The present invention relates to compounds of formula I: wherein R1, R2, R3 and R4 are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: GrantFiled: February 27, 2015Date of Patent: February 27, 2018Assignee: Cancer Research Technology LimitedInventors: Hannah Woodward, Paolo Innocenti, Sebastien Naud, Julian Blagg, Swen Hoelder